NCT00934401撤回不适用
Positron Emission Mammography With 3'-Deoxy-3'-[18F] Fluorothymidine (FLT PEM) for Evaluation of Response to Neoadjuvant Chemotherapy in Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Uptake of FLT (SUV) within the tumor
研究概览
简要总结
Positron Emission Tomography Imaging with 3-Deoxy-3'-[18F]Fluorothymidine (FLT) can selectively identify proliferating and non-proliferating tissues, including tumors. FLT uptake in the tumor is an indirect marker of DNA synthesis activity, which is a target of chemotherapy. Our hypothesis is that early change in FLT uptake in tumor with chemotherapy will predict pathological response to neoadjuvant therapy in breast cancer. Tumor uptake of FLT will be imaged and measured with positron emission mammography (PEM), a PET scanner optimized for breast imaging with a significantly improved resolution compared to conventional whole-body PET imaging systems.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and willingness to sign a written informed consent document.
- •Subject must have histologically confirmed breast cancer.
- •Subject must be scheduled to receive neoadjuvant chemotherapy followed by surgery for their standard cancer care. Treatment decisions will be made by the treating surgeon and the medical oncologist.
- •Females at least 18 years of age.
- •Karnofsky at least 60% at time of screening.
- •Life expectancy of greater than 6 months.
- •Subject must have normal organ and marrow function (as defined below) within 30 days of study enrollment:
- •leukocytes at least 3,000/microL
- •absolute neutrophil count at least 1,500/microL
- •platelets at least 100,000/microL
- •total bilirubin Equal or less than 1.0 mg/dl
- •AST(SGOT) no greater than 2.5 X institutional upper limit of normal
- •ALT (SGPT) no greater than 2.5 X institutional upper limit of normal
- •Creatinine Equal or less than 1.4 mg/dl
- •BUN Equal or less than 20 mg /dl
- •The effects of FLT on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A screening urine hCG will be administered in the Nuclear Medicine to women of childbearing potential before each FLT scan and pregnant women will not be accepted as subjects in this study.
排除标准
- •Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- •Subject with a Karnofsky score of below
- •Pregnant women are excluded from this study. FLT PET has potential for teratogenic effects. Because there are potentially unknown risks for adverse events in nursing infants secondary to treatment of the mother with FLT, breastfeeding should be discontinued if the mother is imaged with FLT and may not resume for 48 hours after the FLT imaging.
- •Subjects taking nucleoside analog medications such as those used as antiretroviral agents.
结局指标
主要结局
Uptake of FLT (SUV) within the tumor
时间窗: 20 mintues and 60 minutes post injection
次要结局
- Pathologic tumor response(3 months)
研究者
Yusuf Menda
Associate Professor
University of Iowa
研究点 (1)
Loading locations...
相似试验
终止
1 期
FBnTP Imaging of Breast CancerBreast CancerNCT02204462Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4
进行中（未招募）
不适用
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerBrain and Central Nervous System TumorsChronic Myeloproliferative DisordersLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol SpecificLeukemiaLymphomaNCT00935090Barbara Ann Karmanos Cancer Institute80
已完成
不适用
Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a VeinThromboembolismUnspecified Adult Solid Tumor, Protocol SpecificNCT00964275University Hospital, Brest400
终止
1 期
The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver MetastasesLiver NeoplasmsColorectal NeoplasmsNCT00145665Radboud University Medical Center80
Unknown
不适用
18F-FLT PET for Suspicious Findings on Mammography and Breast UltrasoundBreast NeoplasmsNCT01713049National Taiwan University Hospital70